All In Biotech

Drug Trial Radar · NCT05748873

Promising ROd-cone DYstrophy Gene therapY

A Phase I/II Study to Assess the Safety and Tolerability of a Single Subretinal Administration of SPVN06 Gene Therapy in Subjects With Rod-Cone Dystrophy (RCD)

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

33

Actual

Start

Apr 12, 2023

Primary completion

Feb 2027

Study completion Feb 2031

Sponsor

Lead sponsor
SparingVisionIndustry
Sponsor type
Industry
First posted
Mar 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene (Step 1), or in any RCD-causative gene (Step 2).

Conditions

  • Retinitis Pigmentosa

Interventions

  • SPVN06Drug

    AAV-RdCVF-RdCVFL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of the safety and tolerability of a single injection of SPVN06 in subjects with advanced RCD, 12 months after administration of gene therapy.Time frame: Baseline to 12 months after administration of gene therapy

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Bascom Palmer Eye Institute/University of Miami

    Miami, Florida

  • Mass Eye and Ear

    Boston, Massachusetts

  • Casey Eye Institute

    Portland, Oregon

  • UPMC Eye Center

    Pittsburgh, Pennsylvania

  • Retina Foundation of the Southwest

    Dallas, Texas

  • CHNO XV-XX Paris - CIC 1423

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.